Transactions

Aegerion Pharmaceuticals, Inc.’s exclusive Japan outlicensing agreement with Recordati Rare Diseases Inc.

Date Announced:
02/06/2019

client:
Aegerion Pharmaceuticals, Inc.

Status:
Closed – 02/06/2019

Value:
Up to $110 million, plus royalties